1887
  1. Home
  2. Eurosurveillance
  3. Volume 30, Issue 25, 26/Jun/2025
  4. Article
Research Open Access
Like 0
Download

Abstract

BACKGROUND

Respiratory syncytial virus (RSV) is a major cause of morbidity in older adults.

AIM

We aimed to investigate the epidemiology of RSV in adults in five European countries and one region before and during the COVID-19 era.

METHODS

We conducted a retrospective analysis using national hospital admission data from Denmark, England, Finland, the Netherlands, Scotland and regional prospective surveillance data from the Spain-Valencia region. We included patients aged ≥ 18 years hospitalised for respiratory tract infections (RTIs) 2016–2023 and assessed RSV-coded and laboratory-confirmed hospitalisations, intensive care unit (ICU) admissions and mortality.

RESULTS

Hospitalisations associated with RSV varied by country and year but increased with increasing age regardless of the use of RSV-coded or RSV-confirmed data, the country or year. The highest hospitalisation rates were in patients aged ≥ 85 years. We found that RSV-coded hospitalisations underestimated the case numbers when compared with laboratory-confirmed cases by an average of 1.9 (standard deviation (SD): ± 0.9). Admissions to ICU associated with RSV in England and CFR in England and Finland displayed different patterns post-COVID-19 pandemic peak but were not notably higher compared with RTI admissions.

CONCLUSION

Our findings reveal a consistency of RSV hospital admission patterns between European countries in the study period, with higher incidence rates among older patients. The differences between the numbers of RSV-coded and laboratory-confirmed cases highlight the critical need for improved surveillance, diagnostic practices and coding guidelines to better assess the incidence. Our findings could be vital for guiding public health strategies, particularly with the introduction of RSV vaccines for older adults.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2025.30.25.2400624
2025-06-26
2025-06-30
/content/10.2807/1560-7917.ES.2025.30.25.2400624
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/30/25/eurosurv-30-25-4.html?itemId=/content/10.2807/1560-7917.ES.2025.30.25.2400624&mimeType=html&fmt=ahah

References

  1. Lee N, Lui GCY, Wong KT, Li TCM, Tse ECM, Chan JYC, et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis. 2013;57(8):1069-77.  https://doi.org/10.1093/cid/cit471  PMID: 23876395 
  2. Nguyen-Van-Tam JS, O’Leary M, Martin ET, Heijnen E, Callendret B, Fleischhackl R, et al. Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries. Eur Respir Rev. 2022;31(166):220105.  https://doi.org/10.1183/16000617.0105-2022  PMID: 36384703 
  3. Shi T, Denouel A, Tietjen AK, Campbell I, Moran E, Li X, et al. Global disease burden estimates of respiratory syncytial virus-associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis. J Infect Dis. 2020;222(Suppl 7):S577-83.  https://doi.org/10.1093/infdis/jiz059  PMID: 30880339 
  4. Nam HH, Ison MG. Respiratory syncytial virus infection in adults. BMJ. 2019;366:l5021.  https://doi.org/10.1136/bmj.l5021  PMID: 31506273 
  5. Falsey AR, McElhaney JE, Beran J, van Essen GA, Duval X, Esen M, et al. Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness. J Infect Dis. 2014;209(12):1873-81.  https://doi.org/10.1093/infdis/jit839  PMID: 24482398 
  6. Falsey AR, Criddle MC, Walsh EE. Detection of respiratory syncytial virus and human metapneumovirus by reverse transcription polymerase chain reaction in adults with and without respiratory illness. J Clin Virol. 2006;35(1):46-50.  https://doi.org/10.1016/j.jcv.2005.04.004  PMID: 15919236 
  7. Tseng HF, Sy LS, Ackerson B, Solano Z, Slezak J, Luo Y, et al. Severe morbidity and short- and mid- to long-term mortality in older adults hospitalized with respiratory syncytial virus infection. J Infect Dis. 2020;222(8):1298-310.  https://doi.org/10.1093/infdis/jiaa361  PMID: 32591787 
  8. Belongia EA, King JP, Kieke BA, Pluta J, Al-Hilli A, Meece JK, et al. Clinical features, severity, and incidence of RSV illness during 12 consecutive seasons in a community cohort of adults ≥60 years old. Open Forum Infect Dis. 2018;5(12):ofy316.  https://doi.org/10.1093/ofid/ofy316  PMID: 30619907 
  9. Guan XR, Jiang LX, Ma XH, Wang LF, Quan H, Li HY. Respiratory syncytial virus infection and risk of acute myocardial infarction. Am J Med Sci. 2010;340(5):356-9.  https://doi.org/10.1097/MAJ.0b013e3181eecf29  PMID: 20811272 
  10. Blackburn R, Zhao H, Pebody R, Hayward A, Warren-Gash C. Laboratory-confirmed respiratory infections as predictors of hospital admission for myocardial infarction and stroke: time-series analysis of English data for 2004-2015. Clin Infect Dis. 2018;67(1):8-17.  https://doi.org/10.1093/cid/cix1144  PMID: 29324996 
  11. Sáez-López E, Pechirra P, Costa I, Cristóvão P, Conde P, Machado A, et al. Performance of surveillance case definitions for respiratory syncytial virus infections through the sentinel influenza surveillance system, Portugal, 2010 to 2018. Euro Surveill. 2019;24(45):1900140.  https://doi.org/10.2807/1560-7917.ES.2019.24.45.1900140  PMID: 31718741 
  12. Allen KE, Chommanard C, Haynes AK, Erdman DD, Gerber SI, Kim L. Respiratory syncytial virus testing capabilities and practices among National Respiratory and Enteric Virus Surveillance System laboratories, United States, 2016. J Clin Virol. 2018;107:48-51.  https://doi.org/10.1016/j.jcv.2018.08.009  PMID: 30189412 
  13. Drews SJ, Branche AR, Falsey AR, Lee N. What is the role of rapid molecular testing for seniors and other at-risk adults with respiratory syncytial virus infections? J Clin Virol. 2019;117:27-32.  https://doi.org/10.1016/j.jcv.2019.05.010  PMID: 31158780 
  14. Amodio E, Belluzzo M, Genovese D, Palermo M, Pisciotta V, Vitale F. What ‘case definition’ for respiratory syncytial virus infection? Results of a systematic literature review to improve surveillance among the adults. J Public Health (Oxf). 2024;46(3):326-34.  https://doi.org/10.1093/pubmed/fdae066  PMID: 38705841 
  15. Urchueguía-Fornes A, Muñoz-Quiles C, Mira-Iglesias A, López-Lacort M, Mengual-Chuliá B, López-Labrador FX, et al. Ten-year surveillance of respiratory syncytial virus hospitalizations in adults: incidence rates and case definition implications. J Infect Dis. 2025;231(5):e830-9.  https://doi.org/10.1093/infdis/jiaf056  PMID: 39907319 
  16. European Medicines Agency (EMA). First vaccine to protect older adults from respiratory syncytial virus (RSV) infection. Amsterdam: EMA; 26 Apr 2023. Available from: https://www.ema.europa.eu/en/news/first-vaccine-protect-older-adults-respiratory-syncytial-virus-rsv-infection
  17. European Medicines Agency (EMA). First RSV vaccine to protect infants up to 6 months of age and older adults. Amsterdam: EMA; 21 Jul 2023. Available from: https://www.ema.europa.eu/en/news/first-rsv-vaccine-protect-infants-6-months-age-and-older-adults
  18. European Medicines Agency (EMA). mResvia. Amsterdam: EMA; 28 Jun 2024. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/mresvia
  19. Program for Appropriate Technology in Health (PATH). RSV vaccine and mAb snapshot. Seattle: PATH; Feb 2025. Available from: https://www.path.org/our-impact/resources/rsv-vaccine-and-mab-snapshot
  20. Cong B, Koç U, Bandeira T, Bassat Q, Bont L, Chakhunashvili G, et al. Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis. Lancet Infect Dis. 2024;24(4):361-74.  https://doi.org/10.1016/S1473-3099(23)00630-8  PMID: 38141633 
  21. Tang JW, Bialasiewicz S, Dwyer DE, Dilcher M, Tellier R, Taylor J, et al. Where have all the viruses gone? Disappearance of seasonal respiratory viruses during the COVID-19 pandemic. J Med Virol. 2021;93(7):4099-101.  https://doi.org/10.1002/jmv.26964  PMID: 33760278 
  22. Angoulvant F, Ouldali N, Yang DD, Filser M, Gajdos V, Rybak A, et al. Coronavirus disease 2019 pandemic: impact caused by school closure and national lockdown on pediatric visits and admissions for viral and nonviral infections-a time series analysis. Clin Infect Dis. 2021;72(2):319-22.  https://doi.org/10.1093/cid/ciaa710  PMID: 33501967 
  23. Britton PN, Hu N, Saravanos G, Shrapnel J, Davis J, Snelling T, et al. COVID-19 public health measures and respiratory syncytial virus. Lancet Child Adolesc Health. 2020;4(11):e42-3.  https://doi.org/10.1016/S2352-4642(20)30307-2  PMID: 32956616 
  24. Jollivet O, Urchueguía-Fornes A, Chung-Delgado K, Klint Johannesen C, Lehtonen T, Gideonse D, et al. Respiratory syncytial virus hospitalisation burden in children below 18 years in six European countries (2016-2023) pre- and post-COVID-19 pandemic. Int J Infect Dis. 2025;155:107903.  https://doi.org/10.1016/j.ijid.2025.107903  PMID: 40204016 
  25. Mira-Iglesias A, Demont C, López-Labrador FX, Mengual-Chuliá B, García-Rubio J, Carballido-Fernández M, et al. Role of age and birth month in infants hospitalized with RSV-confirmed disease in the Valencia Region, Spain. Influenza Other Respir Viruses. 2022;16(2):328-39.  https://doi.org/10.1111/irv.12937  PMID: 34821055 
  26. Puig-Barberà J, García-de-Lomas J, Díez-Domingo J, Arnedo-Pena A, Ruiz-García M, Limón-Ramírez R, et al. Influenza vaccine effectiveness in preventing influenza A(H3N2)-related hospitalizations in adults targeted for vaccination by type of vaccine: a hospital-based test-negative study, 2011-2012 A(H3N2) predominant influenza season, Valencia, Spain. PLoS One. 2014;9(11):e112294.  https://doi.org/10.1371/journal.pone.0112294  PMID: 25392931 
  27. European Commission (EC). Commission Implementing Decision (EU) 2018/945 of 22 June 2018 on the communicable diseases and related special health issues to be covered by epidemiological surveillance as well as relevant case definitions. Brussels: EC; 2018. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32018D0945
  28. Reeves RM, van Wijhe M, Tong S, Lehtonen T, Stona L, Teirlinck AC, et al. Respiratory syncytial virus-associated hospital admissions in children younger than 5 years in 7 European countries using routinely collected datasets. J Infect Dis. 2020;222(Suppl 7):S599-605.  https://doi.org/10.1093/infdis/jiaa360  PMID: 32815542 
  29. Doty B, Ghaswalla P, Bohn RL, Stoszek SK, Panozzo CA. Incidence of RSV in adults: a comprehensive review of observational studies and critical gaps in information. J Infect Dis. 2024;230(6):e1182-201.  https://doi.org/10.1093/infdis/jiae314  PMID: 38934801 
  30. Havers FP, Whitaker M, Melgar M, Pham H, Chai SJ, Austin E, et al. Burden of respiratory syncytial virus-associated hospitalizations in US adults, October 2016 to September 2023. JAMA Netw Open. 2024;7(11):e2444756.  https://doi.org/10.1001/jamanetworkopen.2024.44756  PMID: 39535791 
  31. Hamid S, Winn A, Parikh R, Jones JM, McMorrow M, Prill MM, et al. Seasonality of respiratory syncytial virus - United States, 2017-2023. MMWR Morb Mortal Wkly Rep. 2023;72(14):355-61.  https://doi.org/10.15585/mmwr.mm7214a1  PMID: 37022977 
  32. Li Y, Kulkarni D, Begier E, Wahi-Singh P, Wahi-Singh B, Gessner B, et al. Adjusting for case under-ascertainment in estimating RSV hospitalisation burden of older adults in high-income countries: a systematic review and modelling study. Infect Dis Ther. 2023;12(4):1137-49.  https://doi.org/10.1007/s40121-023-00792-3  PMID: 36941483 
  33. Onwuchekwa C, Moreo LM, Menon S, Machado B, Curcio D, Kalina W, et al. Underascertainment of respiratory syncytial virus infection in adults due to Diagnostic Testing Limitations: A Systematic Literature Review and Meta-analysis. J Infect Dis. 2023;228(2):173-84.  https://doi.org/10.1093/infdis/jiad012  PMID: 36661222 
  34. Heemskerk S, Spreeuwenberg P, Nair H, Paget J, PROMISE investigators. Comparison of the Oxford COVID-19 government response tracker and the ECDC-JRC response measures database for nonpharmaceutical interventions. Influenza Other Respir Viruses. 2024;18(1):e13249.  https://doi.org/10.1111/irv.13249  PMID: 38179339 
  35. Godoy P, Romero A, Soldevila N, Torner N, Jané M, Martínez A, et al. Influenza vaccine effectiveness in reducing severe outcomes over six influenza seasons, a case-case analysis, Spain, 2010/11 to 2015/16. Euro Surveill. 2018;23(43):1700732.  https://doi.org/10.2807/1560-7917.ES.2018.23.43.1700732  PMID: 30376915 
  36. Vega-Piris L, Carretero SG, Mayordomo JL, Zarzuelo MBR, Río VÁ, García VG, et al. Severity of respiratory syncytial virus compared with SARS-CoV-2 and influenza among hospitalised adults ≥65 years. J Infect. 2024;89(5):106292.  https://doi.org/10.1016/j.jinf.2024.106292  PMID: 39341402 
  37. Bongaarts J. Long-range trends in adult mortality: models and projection methods. Demography. 2005;42(1):23-49.  https://doi.org/10.1353/dem.2005.0003  PMID: 15782894 
  38. Haas LEM, de Lange DW, van Dijk D, van Delden JJM. Should we deny ICU admission to the elderly? Ethical considerations in times of COVID-19. Crit Care. 2020;24(1):321.  https://doi.org/10.1186/s13054-020-03050-x  PMID: 32517776 
  39. Nguyen Y-L, Angus DC, Boumendil A, Guidet B. The challenge of admitting the very elderly to intensive care. Ann Intensive Care. 2011;1(1):29.  https://doi.org/10.1186/2110-5820-1-29  PMID: 21906383 
  40. Korsten K, Adriaenssens N, Coenen S, Butler CC, Verheij TJM, Bont LJ, et al. World Health Organization influenza-like illness underestimates the burden of respiratory syncytial virus infection in community-dwelling older adults. J Infect Dis. 2022;226(Suppl 1):S71-8.  https://doi.org/10.1093/infdis/jiab452  PMID: 34904176 
  41. Johannesen CK, van Wijhe M, Tong S, Fernández LV, Heikkinen T, van Boven M, et al. Age-specific estimates of respiratory syncytial virus-associated hospitalizations in 6 European countries: a time series analysis. J Infect Dis. 2022;226(Suppl 1):S29-37.  https://doi.org/10.1093/infdis/jiac150  PMID: 35748871 
  42. Osei-Yeboah R, Johannesen CK, Egeskov-Cavling AM, Chen J, Lehtonen T, Fornes AU, et al. Respiratory syncytial virus-associated hospitalization in adults with comorbidities in 2 European countries: a modeling study. J Infect Dis. 2024;229(Supplement_1):S70-7.  https://doi.org/10.1093/infdis/jiad510  PMID: 37970679 
  43. Muñoz-Quiles C, López-Lacort M, Urchueguía A, Díez-Domingo J, Orrico-Sánchez A. Risk of cardiovascular events after influenza: a population-based self-controlled case series study, Spain, 2011-2018. J Infect Dis. 2024;230(3):e722-31.  https://doi.org/10.1093/infdis/jiae070  PMID: 38330324 
  44. Meerhoff TJ, Simaku A, Ulqinaku D, Torosyan L, Gribkova N, Shimanovich V, et al. Surveillance for severe acute respiratory infections (SARI) in hospitals in the WHO European region - an exploratory analysis of risk factors for a severe outcome in influenza-positive SARI cases. BMC Infect Dis. 2015;15(1):1.  https://doi.org/10.1186/s12879-014-0722-x  PMID: 25567701 
  45. Teirlinck AC, Johannesen CK, Broberg EK, Penttinen P, Campbell H, Nair H, et al. New perspectives on respiratory syncytial virus surveillance at the national level: lessons from the COVID-19 pandemic. Eur Respir J. 2023;61(4):2201569.  https://doi.org/10.1183/13993003.01569-2022  PMID: 37012081 
Hospitalisation trends of respiratory syncytial virus (RSV) infection in adults, six European countries, before and during COVID-19, 2016 to 2023
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Arantxa+Urchuegu%C3%ADa-Fornes&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Urchueguía-Fornes Arantxa</a>, <a href="/search?value1=Richard+Osei-Yeboah&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Osei-Yeboah Richard</a>, <a href="/search?value1=Ombeline+Jollivet&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Jollivet Ombeline</a>, <a href="/search?value1=Caroline+Klint+Johannesen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Johannesen Caroline Klint</a>, <a href="/search?value1=Toni+Lehtonen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Lehtonen Toni</a>, <a href="/search?value1=Michiel+van+Boven&option1=author&noRedirect=true" class="nonDisambigAuthorLink">van Boven Michiel</a>, <a href="/search?value1=David+Gideonse&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Gideonse David</a>, <a href="/search?value1=Rachel+A+Cohen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Cohen Rachel A</a>, <a href="/search?value1=Alejandro+Orrico-S%C3%A1nchez&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Orrico-Sánchez Alejandro</a>, <a href="/search?value1=Rolf+Kramer&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kramer Rolf</a>, <a href="/search?value1=Thea+K+Fischer&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Fischer Thea K</a>, <a href="/search?value1=Terho+Heikkinen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Heikkinen Terho</a>, <a href="/search?value1=Harish+Nair&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Nair Harish</a>, <a href="/search?value1=Harry+Campbell&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Campbell Harry</a>, <a href="/search?value1=on+behalf+of+the+PROMISE+investigators&option1=author&noRedirect=true" class="nonDisambigAuthorLink">on behalf of the PROMISE investigators</a></span>. Hospitalisation trends of respiratory syncytial virus (RSV) infection in adults, six European countries, before and during COVID-19, 2016 to 2023. <a href="/content/ecdc">Euro Surveill.</a> 2025;30(25):pii=2400624. <a href="https://doi.org/10.2807/1560-7917.ES.2025.30.25.2400624" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2025.30.25.2400624</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 19 Sept 2024;&nbsp;&nbsp; <span class="generated">Accepted</span>: 29 Mar 2025 </span> </p>
/content/10.2807/1560-7917.ES.2025.30.25.2400624
/content/10.2807/1560-7917.ES.2025.30.25.2400624
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error